Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Operating Expenses (2020 - 2025)

Foghorn Therapeutics has reported Operating Expenses over the past 6 years, most recently at $33.1 million for Q4 2025.

  • Quarterly results put Operating Expenses at $33.1 million for Q4 2025, up 23.32% from a year ago — trailing twelve months through Dec 2025 was $117.3 million (down 6.38% YoY), and the annual figure for FY2025 was $117.3 million, down 6.38%.
  • Operating Expenses for Q4 2025 was $33.1 million at Foghorn Therapeutics, up from $26.7 million in the prior quarter.
  • Over the last five years, Operating Expenses for FHTX hit a ceiling of $38.6 million in Q1 2023 and a floor of $23.4 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $31.7 million (2022), compared with a mean of $31.2 million.
  • Biggest five-year swings in Operating Expenses: soared 70.62% in 2021 and later decreased 15.81% in 2025.
  • Foghorn Therapeutics' Operating Expenses stood at $28.8 million in 2021, then increased by 25.26% to $36.1 million in 2022, then fell by 13.43% to $31.2 million in 2023, then decreased by 13.98% to $26.9 million in 2024, then rose by 23.32% to $33.1 million in 2025.
  • The last three reported values for Operating Expenses were $33.1 million (Q4 2025), $26.7 million (Q3 2025), and $28.7 million (Q2 2025) per Business Quant data.